Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

65 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

53 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07015853 2025-08-27

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Phase 2 Not yet recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT06951399 2025-07-22

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Phase NA Not yet recruiting

98 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04901741 2025-06-27

OPTIMUS

Phase 2 Not yet recruiting

60 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

ILLUMINE

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

NEO COMBAT XL

PLANET

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

PRELUDE

RESET C2

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

BLP-HCC

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

META-1

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

PANDA-VAC

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

TeLuRide-008

Chrono-EVP

MATVAC-1

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Clinical Trial of TB511 in Advanced Solid Tumors

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

ADAPT-TN-IV

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

LumOnate

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

OPTIMUS